Date: 2014-11-04
Type of information: Collaboration agreement
Compound: sustained-release protein formulation
Company: Carlina Technologies (France) GenBiotech (France)
Therapeutic area: Bone diseases
Type agreement: collaboration
Action mechanism:
Disease: bone and cartilage repair
Details: * On November 4, 2014, CarlinaTechnologies, a biotechnology company specialized in the development of nanomedicines, announced the signing of a collaborative agreement with GenBiotech, a spinoff of the Laboratoires Genévrier, for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair. The development of the product will utilize the patented technology platform PEPTIDOTs™ owned by Carlina Technologies. PEPTIDOTS is a process allowing the encapsulation of therapeutic peptides and proteins without altering their structure, therefore maintaining their full biological activity. This agreement provides an option for GenBiotech to acquire exclusive worldwide rights on Carlina Technologies’ platform PEPTIDOTS to develop, sub-license, or commercialize this product specifically for cartilage repair for animal health. The result of the collaboration for Carlina Technologies will also serve as a proof-of-concept supporting the use of the PEPTIDOTS platform with a number of other therapeutic proteins, including antibodies, growth factors and interleukins. CarlinaTechnologies will aim to collaborate with other pharmaceutical companies involved in protein-based therapeutics that could benefit from its technology platforms.
Financial terms: Financial details were not disclosed.
Latest news:
